153 related articles for article (PubMed ID: 35530644)
1. Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients.
Nakamura N; Kaida D; Tomita Y; Miyata T; Miyashita T; Fujita H; Kinami S; Ueda N; Takamura H
Cancer Diagn Progn; 2022; 2(3):293-299. PubMed ID: 35530644
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
4. The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.
Jia YX; Li TF; Zhang DD; Fan ZM; Fan HJ; Yan J; Chen LJ; Tang H; Qin YR; Li XY
Onco Targets Ther; 2016; 9():5919-5929. PubMed ID: 27729801
[TBL] [Abstract][Full Text] [Related]
5. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
6. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
[TBL] [Abstract][Full Text] [Related]
7. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.
Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Breast; 2020 Dec; 54():235-241. PubMed ID: 33166784
[TBL] [Abstract][Full Text] [Related]
8. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
9. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
12. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
Yang L; Li W; Lu Z; Lu M; Zhou J; Peng Z; Zhang X; Wang X; Shen L; Li J
BMC Cancer; 2022 Apr; 22(1):355. PubMed ID: 35365123
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer.
Kahraman S; Yalcin S
Onco Targets Ther; 2021; 14():4149-4162. PubMed ID: 34285507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
[TBL] [Abstract][Full Text] [Related]
16. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
18. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
Urabe M; Ushiku T; Seto Y; Fukayama M
Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.
Honma Y; Shimada Y; Takashima A; Iwasa S; Kato K; Hamaguchi T; Yamada Y; Taniguchi H; Sekine S; Kushima R
Int J Clin Oncol; 2014 Oct; 19(5):863-70. PubMed ID: 24218279
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.
Dang HZ; Yu Y; Jiao SC
World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
